Abstract:Hereditary spastic paraplegia (HSP) associated with thin corpus callosum (TCC) is an autosomal recessive complicated HSP characterized by normal motor development, followed by slowly progressive spastic paraparesis and mental deterioration. Recently, mutations of the SPG11 gene encoding the spatacsin protein have been identified as a major cause of HSP-TCC. SPG11 is located on chromosome 15q21.1, contains 40 exons and encodes a protein of 2,443 amino acids. Spatacsin function is not yet known, however, its widespread expression in the central nervous system and its highly conserved sequence among species indicate an important and essential role. Up to date, 10 mutations including four nonsense mutations, four small deletions and two small insertions of the SPG11 gene were found in 12 families of ARHSP-TCC. Here, we described two novel mutations of the SPG11 gene in two unrelated Chinese patients with HSP-TCC. Patient 1, a 24-year-old man, presented with a progressive speech disorder with mental deterioration impairing school performance(s) from the age of 7 years on. From the age of 14 onwards, he also developed leg stiffness and gait disturbance. There was no consanguinity, family history was unremarkable, and his birth and motor development had been normal. Neurologic examination at age 24 showed dysarthria, left foot muscle atrophy, lower limb symmetric spasticity, upper limb ataxia, and unsteady tandem walking. His Mini Mental State Examination (MMSE) score was 14/30. Ceruloplasmin was normal. Motor nerve conduction of the left peroneal nerve showed lowered amplitude. EMG examination showed denervation potentials in the anterior tibial muscles and the left gastrocnemius muscle. Brain MR Images (Fig 1a–c) disclosed thinning of the corpus callosum, especially in its anterior parts, slight hyperintense signal alterations in the periventricular white matter, as well as mild thalamic and cerebellar atrophy. Spinal cord MRI was normal. Patient 2, a 26-year-old man, born from consanguineous parents, suffered from slowly progessive dysarthria, accompanied by a gait disorder from the age of 18 onwards. He had difficulty in walking without assistance by the age of 23. His MMSE score was 6/30. Besides the dysarthria, and paraspasticity, there was additional hand muscle atrophy, and mild weakness of the lower limbs. Nerve conduction was normal. In the brain MRI (Fig 1d–f) there was slight enlargement of the lateral ventricles and a thin corpus callosum. Spine MRI revealed atrophy of the thoracic cord. Some of the dysarthria and spasticity symptoms of the patients improved under treatment with baclofen (45 mg/day) and D2 receptor agonist (Piribedil, 50 mg bid). Sequencing of the SPG11 gene revealed a novel homozygous small deletion (c.4307_4308del, Fig. 2A) in exon 25 in the first patient leading to a frameshift and early termination at amino acid residue 1,442. This was not found in 100 control chromosomes studied by direct sequencing (Fig. 2B). A homozygous c.5977C>T substitution was found in exon 31 in the second patient (Fig. 2C), leading to a termination at amino acid residue 1,993. All PCR products of exon 31 of 50 healthy controls were cut into 210 bp and 320 bp with Sall (Fig. 2E). This restriction site which is found in normal chromosomes was lost in patient 2. A homozygous c.833A>G substitution was also detected in exon 5 of the same patient (Fig. 2F), leading to an amino acid change (p.278N>S). This is likely a polymorphism since 4 out of 50 healthy controls were heterozygote for the same change (Fig. 2G). The two novel mutations found in the present report lead to a stop codon, providing further evidence for a loss of function mechanism. The difference of the severity and onset age of these two patients may be due to differences in spatacsin dysfunction resulting from the two mutations. However, a precise genotype-phenotype correlation is not yet possible, due to the small overall number of patients with SPG11 mutations described so far. This report points to the importance of screening the SPG11 gene for additional mutations in more families with HSP-TCC.

Inhibiting mitochondrial fission rescues degeneration in hereditary spastic paraplegia neurons

Novel Mutations in the SPAST Gene Cause Hereditary Spastic Paraplegia.

L-3-n-Butylphthalide Protects HSPB8 K141N Mutation-Induced Oxidative Stress by Modulating the Mitochondrial Apoptotic and Nrf2 Pathways

Pharmacological rescue of mitochondrial and neuronal defects in SPG7 hereditary spastic paraplegia patient neurons using high throughput assays

Liver-X-receptor agonists rescue axonal degeneration in SPG11-deficient neurons via regulating cholesterol trafficking

Mouse models for hereditary spastic paraplegia uncover a role of PI4K2A in autophagic lysosome reformation

Cul-4 inhibition rescues spastin levels and reduces defects in hereditary spastic paraplegia models

Pluripotent Stem Cells as a Preclinical Cellular Model for Studying Hereditary Spastic Paraplegias

A Novel SPAST Mutation Results in Spastin Accumulation and Defects in Microtubule Dynamics

Decoding Hereditary Spastic Paraplegia Pathogenicity Through Transcriptomic Profiling

Autophagy Induction in C12orf65&nbsp;Mutation-related Autosomal Recessive Hereditary Spastic Paraplegia&nbsp;

Effect of spastic paraplegia mutations in KIF5A kinesin on transport activity

Rapid degeneration of iPSC-derived motor neurons lacking Gdap1 engages a mitochondrial-sustained innate immune response

Decreasing ganglioside synthesis delays motor and cognitive symptom onset in knockout mice

A Missense Mutation in SLC33A1, Which Encodes the Acetyl-Coa Transporter, Causes Autosomal-Dominant Spastic Paraplegia (SPG42).

FBXL17/spastin axis as a novel therapeutic target of hereditary spastic paraplegia

Autophagy Induction in C12orf65 Mutation-related Autosomal Recessive Hereditary Spastic Paraplegia

Two Novel Mutations in the SPG11 Gene Causing Hereditary Spastic Paraplegia Associated with Thin Corpus Callosum

Axon demyelination and degeneration in a zebrafish model of hereditary spastic paraplegia

Progress of pathogenesis of hereditary spastic paraplegia type 4

Hereditary spastic paraplegias proteome: common pathways and pathogenetic mechanisms